Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02618577 |
|
Recruitment Status :
Terminated
(following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.)
First Posted : December 1, 2015
Last Update Posted : July 28, 2023
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Atrial High Rate Episodes | Drug: Edoxaban Drug: ASA | Phase 3 |
Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional ECG recordings. It is well established that a large proportion of AF episodes remain undiagnosed ("silent AF"), and many of these patients present with a stroke as the first clinical sign of AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap. Pacemakers, defibrillators, and cardiac resynchronisation devices already provide automated algorithms alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE. A sizeable portion of these patients develops clinically detected AF over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF. In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHREs.
The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial, edoxaban prevented strokes at least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 2608 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Phase 3b |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET |
| Actual Study Start Date : | February 2016 |
| Actual Primary Completion Date : | December 31, 2022 |
| Actual Study Completion Date : | December 31, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Edoxaban
Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics: Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole. |
Drug: Edoxaban
Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics: Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole. Other Names:
|
|
Active Comparator: ASA or Placebo
Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
|
Drug: ASA
ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripherial or coronary artery disease, a prior myocardial infarction, or a prior stroke.
Other Name: ASS |
- stroke, systemic embolism, or cardiovascular death [ Time Frame: 28 months ]Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death
- Components of the primary outcome [ Time Frame: 28 months ]All-cause death Major bleeding events according to the ISTH definitions Quality of life changes at 12 and 24 months compared to baseline Patient satisfaction at 12 and 24 months compared to baseline Cost effectiveness and health resource utilisation Patient autonomy changes at 12 and 24 months compared to baseline including chronic consequences of stroke (aphasia, hemianopia ("mild stroke")) Cognitive function at 12 and 24 months compared to baseline
- Major Adverse Cardiac Events (MACEs: cardiac death, myocardial infarction, acute coronary syndrome (ACS) [ Time Frame: 28 months ]PCI, CABG
- All-cause death [ Time Frame: 28 months ]All-cause death
- Major bleeding events [ Time Frame: 28 months ]according to the International Society on Thrombosis and Haemostasis (ISTH) definitions
- Quality of life changes at 12 and 24 months compared to baseline [ Time Frame: 28 months ]assessed by EQ-5D including its visual-analogue scale and by the Karnofsky scale
- Patient satisfaction at 12 and 24 months compared to baseline [ Time Frame: 28 months ]assessed by PACT-Q
- Cost effectiveness and health resource utilisation [ Time Frame: 28 months ]estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies
- Changes of autonomy status in patients with stroke during study participation [ Time Frame: 28 Months ]potentially assessed at each FU visit by modified Rankin scale; a maximum of 2 subsequent assessments in FU per patient with stroke should be performed
- Cognitive function [ Time Frame: 28 months ]MoCA test at 12 and 24 months compared to baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 65 Years and older (Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation
- AHRE detection feature activated for adequate detection of AHRE (refer to Appendix XIII)
- AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally. Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible
- Provision of signed informed consent
- Age ≥ 65 years
In addition, at least one of the following cardiovascular conditions leading to a modified CHA2DS2VASc score of 2 or more:
- Age ≥ 75 years
- Heart failure (clinically overt or LVEF < 45%)
- Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihyper-tensive therapy or resting blood pressure > 145/90 mmHg)
- Diabetes mellitus
- Prior stroke or transient ischemic attack (TIA)
- Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE])
- Provision of signed informed consent
Exclusion Criteria:
- Any disease that limits life expectancy to less than 1 year
- Participation in another controlled clinical trial, either within the past two months or still ongoing
- Previous participation in the present trial NOAH - AFNET 6
- Drug abuse or clinically manifest alcohol abuse
- Any history of overt AF or atrial flutter
- Indication for oral anticoagulation (e.g. deep venous thrombosis)
- Contraindication for oral anticoagulation in general
- Contraindication for edoxaban as stated in the current SmPC
- Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present
- Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation
- End stage renal disease (creatinine clearance (CrCl) < 15 ml/min as calculated by the Cockcroft-Gault method)
- All persons exempt from participation in a clinical trial by law
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02618577
| Austria | |
| Several Sites | |
| Multiple Locations, Austria | |
| Belgium | |
| Several Sites | |
| Multiple Locations, Belgium | |
| Bulgaria | |
| Several | |
| Multiple Locations, Bulgaria | |
| Czechia | |
| Several | |
| Multiple Locations, Czechia | |
| Denmark | |
| Several | |
| Multiple Locations, Denmark | |
| France | |
| Several | |
| Multiple Locations, France | |
| Germany | |
| Several Sites | |
| Multiple Locations, Germany | |
| Greece | |
| Several | |
| Multiple Locations, Greece | |
| Hungary | |
| Several | |
| Multiple Locations, Hungary | |
| Italy | |
| Several | |
| Multiple Locations, Italy | |
| Netherlands | |
| Several | |
| Multiple Locations, Netherlands | |
| Poland | |
| Several | |
| Multiple Locations, Poland | |
| Portugal | |
| Several | |
| Multiple Locations, Portugal | |
| Romania | |
| Several | |
| Multiple Locations, Romania | |
| Spain | |
| Several | |
| Multiple Locations, Spain | |
| Sweden | |
| Several | |
| Multiple Locations, Sweden | |
| Ukraine | |
| Several | |
| Multiple Locations, Ukraine | |
| United Kingdom | |
| Several | |
| Multiple Locations, United Kingdom | |
| Principal Investigator: | Paulus Kirchhof, Prof. Dr. | University Clinic of Hamburg-Eppendorf, Hamburg, Germany |
Publications:
| Responsible Party: | Atrial Fibrillation Network |
| ClinicalTrials.gov Identifier: | NCT02618577 |
| Other Study ID Numbers: |
NOAH - AFNET 6 2015-003997-33 ( EudraCT Number ) |
| First Posted: | December 1, 2015 Key Record Dates |
| Last Update Posted: | July 28, 2023 |
| Last Verified: | July 2023 |
|
Anticoagulation Atrial High Rate Episodes Atrial Fibrillation VKA NOAC |
|
Edoxaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors |
Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants |